Nanotechnology synergized immunoengineering for cancer.

Area of Science:

• Immunology and Nanotechnology in Oncology

Background:

• Conventional cancer immunotherapy faces challenges with unpredictable efficacy and off-target effects.
• There is a significant unmet clinical need for improved immunotherapy strategies.

Purpose of the Study:

• To review the role of nanotechnology in advancing cancer immunotherapy.
• To explore biomaterials-driven nanotechnology for personalized nanomedicines, vaccines, and localized tumor modulation.
• To summarize recent advances in combinatorial therapies for challenging tumors.

Main Methods:

• Overview of design and clinical principles of nanotechnology in cancer immunotherapy.
• Summary of recent highlights and advances in combinatorial therapies.
• Analysis of key steps and parameters for clinical success.

Main Results:

• Nanotechnology offers multimodality and multiplex targeting to overcome immunotherapy limitations.
• Nanotechnology enables programming of pharmacodynamics, pharmacokinetics, and delivery of immunomodulatory agents.
• Potential for improved therapeutic benefits through localized priming at tumor sites.

Conclusions:

• Biomaterials-driven nanotechnology presents promising strategies for personalized nanomedicines, vaccines, and localized tumor modulation.
• Integration of nanotechnology and immunology offers synergistic opportunities for durable cancer treatment responses.
• Recent advances focus on combinatorial therapies for cold and complicated tumors, with key parameters for clinical success identified.